Bio-Techne Corporation (TECH)
Bio-Techne provides the essential tools, proteins, and diagnostic kits that scientists use to research diseases and develop new life-saving medicines.
Is Bio-Techne Corporation a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: High gross margins show strong pricing power. Worth weighing: High valuation metrics suggest a premium price. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Bio-Techne Corporation actually fallen?
Over the last 2 years of daily prices, Bio-Techne Corporation fell as much as −47% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
The company becomes a core supplier for a major medical breakthrough.
Long-term decline in scientific research investment.
What does Bio-Techne Corporation do?
Think of Bio-Techne as a high-end supplier for the world's laboratories, selling the specialised chemicals and equipment needed for complex biological research. Its role as a trusted partner to pharmaceutical companies and universities that need reliable, high-quality materials for their experiments is where the money lies. The question to follow is whether their sales recover, since they've recently seen a slight dip in revenue despite a significant jump in their bottom-line profits.
On our factor screen it looks strongest on momentum and quality, and weakest on value.
- ✓Pays a dividend - about 0.4% a year
- !High P/E of 103 - big growth is already priced in
- ✓Low debt - a sturdier balance sheet
- Momentum screens high (83/100)
- High gross margins show strong pricing power
- Essential role in the global scientific research chain
- Significant recent growth in earnings
- Value screens low (26/100)
- Sensitivity to government and private research funding cuts
- High share price volatility due to a beta above 1
- Dependence on the success of third-party drug development
What do Bio-Techne Corporation's numbers mean?
How much money does Bio-Techne Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Bio-Techne Corporation pay a dividend?
Yes - Bio-Techne Corporation currently pays a dividend of about 0.4% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
What do the numbers say about Bio-Techne Corporation's dividend?
There's no rating here, and we don't judge whether the dividend will continue - that would be advice. Here are the figures income investors usually look at, and what each one means, so you can weigh it up yourself.
Figures are from the latest available data and can be distorted by one-off results. Past payments don't predict future ones, and a dividend can be cut at any time. This lays out the numbers to help you understand them - it is not a view on what will happen.
When does Bio-Techne Corporation report earnings, and how did recent quarters go?
Bio-Techne Corporation is next scheduled to report on about 2026-08-05 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-06 | $0.53 | $0.53 | In line |
| 2026-02-04 | $0.43 | $0.46 | Beat +6% |
| 2025-11-05 | $0.42 | $0.42 | In line |
| 2025-08-06 | $0.50 | $0.53 | Beat +6% |
| 2025-05-07 | $0.51 | $0.56 | Beat +10% |
| 2025-02-05 | $0.39 | $0.42 | Beat +8% |
Across the last 6 quarters here, Bio-Techne Corporation came in ahead of what analysts expected 4 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Bio-Techne Corporation?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Bio-Techne Corporation?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High gross margins show strong pricing power
- Essential role in the global scientific research chain
- Significant recent growth in earnings
- High valuation metrics suggest a premium price
- Recent decline in overall revenue
- Low return on equity: How much profit the company makes for each £1 shareholders have put in. Higher usually means a more efficient business. compared to some peers
- Sensitivity to government and private research funding cuts
- High share price volatility due to a beta above 1
- Dependence on the success of third-party drug development
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained period of revenue growth returning to double digits
- A significant drop in the P/E ratio without a corresponding fall in share price
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.